'''د کوویډ-۱۹ اکسفورډ-اسټرازېنکا واکسین''' چې د '''AZD1222''' کود په مرسته پېژندل کېږي او په کوویشېلډ (Covishield) او واک‌وریا (Vaxzevria) سوداګریزو نومونو پلورل کېږي، د کوویډ-۱۹ د مخنیوي لپاره یو ویروس لېږدوونکی واکسین دی. په بریتانیا کې د اکسفورډ پوهنتون او بریتانیايي-سویډني شرکت اسټرازېنکا له‌خوا جوړ شوی او شمپانزي ChaAdOx1 اډنوویروس د لېږدوونکي په توګه کاروي. دا واکسین د عضلاتو له لارې تزریق کېږي. په ۲۰۲۰ کال کې شویو څېړنو وښوده چې تر لومړي ډوز ۲۲ ورځې وروسته د کوویډ-۱۹ په مخنیوي کې د دغه واکسین اغېزناکتیا ۷۶ سلنه او تر دویم ډوز وروسته ۸۱.۳ سلنه ده. په سکاټلنډ کې یوې بلې څېړنې وښوده چې دا واکسین تر دویم ډوز وروسته د کوویډ-۱۹ د الفا بڼې په مقابل کې ۸۱ سلنه او د ډلټا بڼې په مقابل کې ۶۱ سلنه اغېزناک دی.<ref name="AZ CDC ACIP">{{cite web|url=https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Villafana.pdf|title=AstraZeneca COVID-19 Vaccine (AZD1222)|publisher=AstraZeneca|date=27 January 2021|access-date=7 March 2021|archive-date=27 January 2021|archive-url=https://web.archive.org/web/20210127150708/https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/02-COVID-Villafana.pdf|url-status=live}}</ref><ref>{{cite news|date=4 March 2021|title=Covishield and Covaxin: What we know about India's Covid-19 vaccines|work=BBC News|url=https://www.bbc.com/news/world-asia-india-55748124|access-date=8 March 2021|archive-date=7 March 2021|archive-url=https://web.archive.org/web/20210307222320/https://www.bbc.com/news/world-asia-india-55748124|url-status=live}}</ref><ref>{{Cite web|date=30 March 2021|title=AstraZeneca vaccine renamed 'Vaxzevria'|url=https://www.brusselstimes.com/news/eu-affairs/162559/astrazeneca-vaccine-now-renamed-as-vaxzevria-ema-european-eu-uk-swedish-lakemedelsverket/|access-date=6 April 2021|website=The Brussels Times|archive-date=31 March 2021|archive-url=https://web.archive.org/web/20210331165438/https://www.brusselstimes.com/news/eu-affairs/162559/astrazeneca-vaccine-now-renamed-as-vaxzevria-ema-european-eu-uk-swedish-lakemedelsverket/|url-status=live}}</ref><ref name="NCT04400838">{{cite web|title=Investigating a Vaccine Against COVID-19|url=https://clinicaltrials.gov/ct2/show/NCT04400838|website=[[ClinicalTrials.gov]]|publisher=[[United States National Library of Medicine]]|type=Registry|id=NCT04400838|date=26 May 2020|access-date=14 July 2020|archive-date=11 October 2020|archive-url=https://web.archive.org/web/20201011084750/https://clinicaltrials.gov/ct2/show/NCT04400838/|url-status=live}}</ref><ref name="EudraCT-2020-001228-32">{{cite web|url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB|title=A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19|website=EU Clinical Trials Register|publisher=European Union|type=Registry|id=[[EudraCT]] 2020-001228-32|date=21 April 2020|access-date=3 August 2020|archive-date=5 October 2020|archive-url=https://web.archive.org/web/20201005201654/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB|url-status=live}}</ref><ref name="ISRCTN89951424">{{cite journal|title=A Phase III study to investigate a vaccine against COVID-19|website=ISRCTN|type=Registry|id=ISRCTN89951424|doi=10.1186/ISRCTN89951424|date=May 2020|vauthors=O'Reilly P|doi-access=free|title-link=doi}}</ref><ref name="pmid33306989">{{cite journal|vauthors=Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJ, Emary KR, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SH, Izu A, Jackson S, Jenkin D, Joe CC, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AV, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DP, Vekemans J, Villafana TL, Watson ME, Williams CJ, Douglas AD, Hill AV, Lambe T, Gilbert SC, Pollard AJ|title=Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK|journal=Lancet|volume=397|issue=10269|pages=99–111|date=January 2021|pmid=33306989|pmc=7723445|doi=10.1016/S0140-6736(20)32661-1|issn=0140-6736}}</ref><ref name="Voysev_Feb21">{{cite journal|vauthors=Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJ, Emary KR, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CC, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AV, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DP, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AV, Lambe T, Gilbert SC, Pollard AJ|display-authors=6|title=Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials|journal=Lancet|volume=397|issue=10277|pages=881–891|date=February 2021|pmid=33617777|pmc=7894131|doi=10.1016/S0140-6736(21)00432-3|doi-access=free|title-link=doi}}</ref>

دا واکسین د یخچال د سوړوالي په درجه کې پایدار دی او د خوندیتوب ښې ځانګړنې لري. ځینې جانبي عوارض هم ورسره شته چې د تزریق په ځای کې درد، د سر درد او زړه بدوالی دي، خو دا عوارض د څو ورځو په جریان کې له منځه ځي. ډېر کم امکان لري چې شدید حساسیت هم ورسره پېښ شي؛ د بریتانیا د درملو او روغتیایي محصولاتو د تنظیم مرکز د ۲۰۲۱ کال د اپرېل میاشتې تر ۱۴مې نېټې پورې په شاوخوا ۲۱.۲ میلیونو واکسینونو کې د دغه حساسیت ۲۶۸ موارد ثبت کړي دي. دغه واکسین په ډېرو کمو مواردو کې (چې په ۱۰۰۰۰۰ کسانو کې شاوخوا ۱ کس کېږي) د وینې د ټینګېدو (یعنې تر کوویډ-۱۹ واکسین وروسته د امبولي او ترومبوټیک پېېښو) خطر لرلی دی. د اروپا د درملو مرکز وايي چې د ۲۰۲۱ کال د اپرېل میاشتې تر ۴مې نېټې پورې په اروپا کې د واکسین شویو ۳۴ میلیونو کسانو تر منځ په ټولیز ډول د وینې د ټېنګېدو ډېر کم ۲۲۲ موارد ثبت شوي (چې ۰.۰۰۰۷ سلنه کېږي).<ref name="voxcom">{{cite web|vauthors=Belluz J|date=23 November 2020|title=Why the AstraZeneca-Oxford Covid-19 vaccine is different|url=https://www.vox.com/21590994/oxford-vaccine-results-covid-19-astrazeneca-trial-pfizer-moderna|access-date=26 November 2020|website=[[Vox (website)|Vox]]|archive-date=29 January 2021|archive-url=https://web.archive.org/web/20210129080053/https://www.vox.com/21590994/oxford-vaccine-results-covid-19-astrazeneca-trial-pfizer-moderna|url-status=live}}</ref><ref name="yellow20210228">{{cite web|title=Coronavirus Vaccine : Summary of Yellow Card reporting|access-date=|quotation=It is known from the clinical trials that the more common side effects for both vaccines can occur at a rate of more than one in 10 doses (for example, local reactions or symptoms resembling transient flu-like symptoms)|url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/968411/Coronavirus_vaccine_-_summary_of_Yellow_Card_reporting_28.02.21.pdf|archive-date=16 March 2021|archive-url=https://web.archive.org/web/20210316203656/https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/968411/Coronavirus_vaccine_-_summary_of_Yellow_Card_reporting_28.02.21.pdf|url-status=live}}</ref><ref name=":17">{{cite press release|title=AstraZeneca's COVID-19 vaccine: benefits and risks in context|website=[[European Medicines Agency]] (EMA)|date=23 April 2021|url=https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-benefits-risks-context|access-date=23 April 2021|archive-date=23 April 2021|archive-url=https://web.archive.org/web/20210423135312/https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-benefits-risks-context|url-status=live}}</ref><ref name="EMA20210325ANNEX">{{cite web|title=Annex 1: Summary of Product Characteristics|url=https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf|website=[[European Medicines Agency]] (EMA)|access-date=29 March 2021|archive-date=28 March 2021|archive-url=https://web.archive.org/web/20210328160324/https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf|url-status=live}}</ref><ref name="EMA PR 20210407">{{cite press release|title=AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets|website=[[European Medicines Agency]] (EMA)|date=7 April 2021|url=https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood|access-date=9 April 2021|archive-date=20 May 2021|archive-url=https://web.archive.org/web/20210520113049/https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood|url-status=live}} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>

دا واکسین د لومړي ځل لپاره د ۲۰۲۰ کال د ډسمبر میاشتې په ۳۰مه نېټه د بریتانیا د واکسیناسیون په پروګرام کې د کارېدو لپاره تایید شو او لومړنی بې ازمويښته واکسین یې د ۲۰۲۱ کال د جنورۍ میاشتې په ۴مه نېټه تطبیق شو. تر هغه را وروسته دا واکسین په ټوله نړۍ کې د ګڼو روغتیایي مرکزونو له‌خوا تایید شوی دی، لکه د اروپا د درملو مرکز، د استرالیا د درملیزو توکو اداره (چې په لنډمهالي ډول یې د ۲۰۲۱ کال په فبرورۍ میاشت کې تایید کړ) او د دې تر څنګ د بیړنۍ استفادې لپاره د روغتیا د نړیوال سازمان له‌خوا هم تایید شوی دی. د ۲۰۲۲ کال تر جنورۍ میاشتې پورې د دغه واکسین څه باندې ۲.۵ میلیارده ډوزه د نړۍ ۱۷۰ هېوادونو ته رسېدلي وو. ځینې هېوادونه اندېښمن وو چې دا واکسین د ځوانانو لپاره څه ناڅه جانبي عوارض لري، له همدې امله یې یوازې هغو عمر خوړلیو کسانو ته د استفادې اجازه ورکړې ده چې په کوویډ-۱۹ ناروغۍ د اخته کېدو له لوړ ګواښ سره مخامخ دي.<ref name="sbig">{{Cite web|date=8 April 2021|title=Spain, Belgium and Italy restrict AstraZeneca Covid vaccine to older people|url=http://www.theguardian.com/society/2021/apr/08/spain-belgium-and-italy-restrict-astrazeneca-covid-vaccine-to-older-people|access-date=11 April 2021|website=The Guardian|archive-date=9 April 2021|archive-url=https://web.archive.org/web/20210409214804/https://www.theguardian.com/society/2021/apr/08/spain-belgium-and-italy-restrict-astrazeneca-covid-vaccine-to-older-people|url-status=live}}</ref><ref>{{cite web|title=One year anniversary of UK deploying Oxford-AstraZeneca vaccine|url=https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine|website=[[gov.uk]]|access-date=4 January 2022}}</ref><ref>{{cite web|title=Coronavirus disease (COVID-19): Vaccines|url=https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines|access-date=6 March 2021|publisher=[[World Health Organization]] (WHO)|archive-date=18 December 2020|archive-url=https://web.archive.org/web/20201218172257/https://www.who.int/news-room/q-a-detail/coronavirus-disease-%28covid-19%29-vaccines?adgroupsurvey=%7Badgroupsurvey%7D&gclid=EAIaIQobChMIq5CLkoTY7QIVREiRBR1LBAMgEAAYASAAEgIObPD_BwE|url-status=live}}</ref><ref name="Oxford first vac">{{cite news|title=Covid: Brian Pinker, 82, first to get Oxford-AstraZeneca vaccine|url=https://www.bbc.com/news/uk-55525542|publisher=BBC News Online|access-date=4 January 2021|date=4 January 2021|archive-date=18 April 2021|archive-url=https://web.archive.org/web/20210418153403/https://www.bbc.com/news/uk-55525542|url-status=live}}</ref><ref>{{cite news|title=Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK|url=https://www.bbc.com/news/health-55280671|publisher=BBC News Online|access-date=30 December 2020|date=30 December 2020|archive-date=30 December 2020|archive-url=https://web.archive.org/web/20201230070334/https://www.bbc.com/news/health-55280671|url-status=live}}</ref><ref>{{cite press release|title=Second COVID-19 vaccine authorised by medicines regulator|website=GOV.UK|date=30 December 2020|url=https://www.gov.uk/government/news/second-covid-19-vaccine-authorised-by-medicines-regulator|access-date=6 March 2021|archive-date=15 March 2021|archive-url=https://web.archive.org/web/20210315133825/https://www.gov.uk/government/news/second-covid-19-vaccine-authorised-by-medicines-regulator|url-status=live}}</ref><ref>{{cite web|url=https://www.tga.gov.au/covid-19-vaccines-undergoing-evaluation|title=Vaccines undergoing evaluation|date=20 July 2021|publisher=[[Therapeutic Goods Administration]] (TGA)}} AstraZeneca Pty Ltd, ChAdOx1-S [recombinant], Viral vector -- Provisional determination notice -- Provisionally approved on 15 February 2021</ref>

== طبي استفادې ==
د کوویډ-۱۹ اکسفورډ-اسټرازېنکا واکسین په ۱۸ کلنو او تر هغه پورته عمر لرونکو اشخاصو کې د کوویډ-۱۹ د مخنیوي په موخه د SARS-CoV-2 ویروس د سرایت په مقابل کې د خوندیتوب لپاره کارول کېږي. دا درمل دوه ۰.۵ ملي لېتره ډوزونه لري چې په لټوئیډ عضله کې (د مټ پر سر) تزریق کېږي. لومړۍ دوره یې دوه ډوزه ده چې واټن یې له ۴ تر ۱۲ اونیو دی. د روغتیا نړیوال سازمان د دغه واکسین د ښې اغېزناکتیا لپاره سپارښتنه کوي چې د ډوزونو تر منځ یې باید له ۸ تر ۱۲ اونیو واټن وي.<ref name="who-guidance">{{cite techreport|type=Guidance|title=Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience)|id=WHO/2019-nCoV/vaccines/SAGE_recommendation/AZD1222/2021.2|institution=World Health Organization|date=21 April 2021|url=https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1|access-date=12 February 2021|archive-date=8 March 2021|archive-url=https://web.archive.org/web/20210308120516/https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1|url-status=live}}</ref>

د شدیدې ناروغۍ د مخنیوي لپاره یې په روغو لویانو کې د درېیم تقویتي ډوز لپاره اړتیا نه ده لیدل شوې.<ref name="who-guidance2">{{cite techreport|type=Guidance|title=Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience)|id=WHO/2019-nCoV/vaccines/SAGE_recommendation/AZD1222/2021.2|institution=World Health Organization|date=21 April 2021|url=https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1|access-date=12 February 2021|archive-date=8 March 2021|archive-url=https://web.archive.org/web/20210308120516/https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1|url-status=live}}</ref><ref name="who-statement-boosters">{{cite press release|date=10 August 2021|title=Interim statement on COVID-19 vaccine booster doses|url=https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses|publisher=World Health Organization|access-date=2021-08-26}}</ref>

=== اغېزناکتیا ===
په برازیل کې د ۲۰۲۱ کال د جنورۍ میاشتې له ۱۸مې تر ۳۰مې نېټې پورې د یوې څېړنې لومړنۍ موندنې چې پر ۶۱ میلیون کسانو شوې ده، ښيي چې د سرایت، بستري کېدو او مړینو په مقابل کې د دغه واکسین اغېزناکتیا کابو په ټولو عمرونو کې سره ورته ده، خو د دغو ټولو په مقابل کې خوندیتوب په هغو کسانو کې ډېر کم دی چې عمرونه یې تر ۹۰ کلونو لوړ دي چې لامل یې د عمر د ډېرېدو له امله د روغتیایي سیستم زوال بلل کېږي.<ref>{{cite journal|vauthors=Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R, Dean NE, Halloran ME, Huang Y, Fleming TR, Gilbert PB, DeGruttola V|display-authors=6|date=12 September 2020|title=COVID-19 vaccine trials should seek worthwhile efficacy|journal=The Lancet|volume=396|issue=10253|pages=741–743|doi=10.1016/S0140-6736(20)31821-3|issn=0140-6736|pmid=32861315|pmc=7832749|quote=WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.}}</ref><ref>{{Cite journal|display-authors=6|vauthors=Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP|date=May 2021|title=Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection|url=https://www.nature.com/articles/s41591-021-01377-8|journal=Nature Medicine|volume=27|issue=7|pages=1205–1211|doi=10.1038/s41591-021-01377-8|issn=1546-170X|pmid=34002089|s2cid=234769053}}</ref>

== منفي اغېزې ==
په کلینيکي ازمېښتونو کې یې تر ټولو معمول جانبي عوارض خفیف یا متوسط وو او تر واکسیناسیون څو ورځې وروسته له منځه لاړل.

کانګې، اسهال، تبه، پړسوب، د تزریق په ځای کې سوروالی او د وینې د پلېټلېټ ټيټې کچې له هرو ۱۰ کسانو څخه په څه کم ۱ کس کې پېښې شوې دي. د لنفاټیکو غدو غټېدل، د اشتها کموالی، سر ګرځېدل، د خوب ګډوډي، د خېټې درد او خارښ له هرو ۱۰۰ کسانو څخه په څه کم ۱ کس کې پېښ شوي دي.<ref>{{cite journal|vauthors=Cines DB, Bussel JB|title=SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia|journal=The New England Journal of Medicine|volume=384|issue=23|pages=2254–2256|date=June 2021|pmid=33861524|pmc=8063912|doi=10.1056/NEJMe2106315|doi-access=free}}</ref><ref>{{cite journal|vauthors=Lai CC, Ko WC, Chen CJ, Chen PY, Huang YC, Lee PI, Hsueh PR|title=COVID-19 vaccines and thrombosis with thrombocytopenia syndrome|journal=Expert Review of Vaccines|volume=20|issue=8|pages=1027–1035|date=August 2021|pmid=34176415|doi=10.1080/14760584.2021.1949294|publisher=Taylor and Francis Group|s2cid=235661210}}</ref><ref>{{cite journal|vauthors=Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S|title=Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination|journal=The New England Journal of Medicine|volume=384|issue=22|pages=2092–2101|date=June 2021|pmid=33835769|pmc=8095372|doi=10.1056/NEJMoa2104840|doi-access=free}}</ref><ref>{{cite news|last1=Public Health Agency of Canada|first1=[Agence de la santé publique du Canada]|title=Use of AstraZeneca COVID-19 vaccine in younger adults|url=https://www.canada.ca/en/public-health/news/2021/03/use-of-astrazeneca-covid-19-vaccine.html|access-date=4 October 2021|agency=Government of Canada|date=29 March 2021|format=Utilisation du vaccin AstraZeneca contre la COVID-19 chez les jeunes adultes}}</ref>

== تاریخچه ==

=== لومړنۍ پراختیا ===
د ۲۰۲۰ کال په فبرورۍ میاشت کې «جنر انستېتیوت» له ایټالوي شرکت «اډوېنټ اېس.ار.اېل» سره هوکړه وکړه چې د کلینیکي ازمېښتونو لپاره د یوه کاندید واکسین ۱۰۰۰ ډوزه تولید کړي. په لومړیو کې اکسفورډ غوښتل چې د واکسین د تولید او مارکېټېنګ حقونه هر هغه درمل جوړوونکي ته ورکړي چې غواړي دا کار وکړي. خو کله چې «ګېټس بنسټ» له اکسفورډ څخه وغوښتل چې بازار ته د کوویډ-۱۹ واکسین د وړاندې کولو لپاره یو لوی همکار شرکت پیدا کړي، دغه پوهنتون د ۲۰۲۰ کال په مې میاشت کې دا وړاندیز رد کړ. ورپسې د بریتانیا حکومت اکسفورډ وهڅاوه چې په متحدو ایالتونو کې د مېشت شرکت «مېرک انډ کو» پر ځای له اروپا مېشتي شرکت «اسټرازېنکا» سره ګډ کار وکړي. په وال سټرېټ ژورنال کې د ناڅرګندو سرچینو په وینا، د حکومت وزیرانو ځینې داسې اندېښنې هم لرلې چې په متحدو ایالتونو کې تولید شوی واکسین به په بریتانیا کې د لاسرسي وړ نه وي. په «اکسفورډ» او «سپېن اوټ» شرکتونو کې مالي ملاحظاتو هم ښايي له «اسټرازېنکا» سره په شراکت کې رول لرلی وي.<ref name="Vaccitech_OSI">{{cite web|date=23 November 2020|title=The Backstory: Vaccitech and its role in co-inventing the Oxford COVID-19 vaccine|url=https://www.oxfordsciencesinnovation.com/news/the-backstory-vaccitech-and-its-role-in-co-inventing-the-oxford-covid-19-vaccine/|access-date=25 March 2021|publisher=Oxford Sciences Innovation|archive-date=1 May 2021|archive-url=https://web.archive.org/web/20210501164556/https://www.oxfordsciencesinnovation.com/news/the-backstory-vaccitech-and-its-role-in-co-inventing-the-oxford-covid-19-vaccine/|url-status=live}}</ref><ref>{{cite web|url=https://covid19vaccinetrial.co.uk/|title=COVID-19 Oxford Vaccine Trial|publisher=COVID-19 Oxford Vaccine Trial|access-date=11 April 2020|archive-date=28 November 2020|archive-url=https://web.archive.org/web/20201128201533/https://covid19vaccinetrial.co.uk/|url-status=live}}</ref><ref>{{cite web|vauthors=Strasburg J, Woo S|url=https://www.wsj.com/articles/oxford-developed-covid-vaccine-then-scholars-clashed-over-money-11603300412|title=Oxford Developed Covid Vaccine, Then Scholars Clashed Over Money|date=21 October 2020|work=[[The Wall Street Journal]]|access-date=28 January 2021|archive-date=7 February 2021|archive-url=https://web.archive.org/web/20210207122223/https://www.wsj.com/articles/oxford-developed-covid-vaccine-then-scholars-clashed-over-money-11603300412|url-status=live}}</ref><ref>{{cite web|url=https://www.msn.com/en-us/news/world/oxford-developed-covid-vaccine-then-scholars-clashed-over-money/ar-BB1agoI3|title=Oxford Developed Covid Vaccine, Then Scholars Clashed Over Money|website=MSN|access-date=13 March 2021|archive-date=27 January 2021|archive-url=https://web.archive.org/web/20210127221529/https://www.msn.com/en-us/news/world/oxford-developed-covid-vaccine-then-scholars-clashed-over-money/ar-BB1agoI3|url-status=live}}</ref><ref>{{cite news|title=The Oxford vaccine: the trials and tribulations of a world-saving jab|date=26 June 2021|url=https://www.theguardian.com/world/2021/jun/26/the-oxford-vaccine-the-trials-and-tribulations-of-a-world-saving-jab|work=The Guardian|access-date=27 June 2021|archive-date=27 June 2021|archive-url=https://web.archive.org/web/20210627114711/https://www.theguardian.com/world/2021/jun/26/the-oxford-vaccine-the-trials-and-tribulations-of-a-world-saving-jab|url-status=live}}</ref><ref>{{cite news|title=Covid Vaccine Front-Runner Is Months Ahead of Her Competition|date=15 July 2020|url=https://www.bloomberg.com/news/features/2020-07-15/oxford-s-covid-19-vaccine-is-the-coronavirus-front-runner|work=Bloomberg Businessweek|access-date=10 February 2021|archive-date=18 April 2021|archive-url=https://web.archive.org/web/20210418054829/https://www.bloomberg.com/news/features/2020-07-15/oxford-s-covid-19-vaccine-is-the-coronavirus-front-runner|url-status=live}}</ref><ref>{{cite news|title=Bill Gates, the Virus and the Quest to Vaccinate the World|date=23 November 2020|url=https://www.nytimes.com/2020/11/23/world/bill-gates-vaccine-coronavirus.html|work=The New York Times|access-date=10 February 2021|archive-date=20 April 2021|archive-url=https://web.archive.org/web/20210420153808/https://www.nytimes.com/2020/11/23/world/bill-gates-vaccine-coronavirus.html|url-status=live}}</ref><ref>{{cite web|title=They Pledged to Donate Rights to Their COVID Vaccine, Then Sold Them to Pharma|url=https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-with-drugmaker/|website=Kaiser Health News|date=25 August 2020|access-date=28 January 2021|archive-date=7 February 2021|archive-url=https://web.archive.org/web/20210207230036/https://khn.org/news/rather-than-give-away-its-covid-vaccine-oxford-makes-a-deal-with-drugmaker/|url-status=live}}</ref><ref>{{cite web|title=Oxford team to begin novel coronavirus vaccine research|url=https://www.ox.ac.uk/news/2020-02-07-oxford-team-begin-novel-coronavirus-vaccine-research|access-date=2 January 2021|publisher=University of Oxford|archive-date=28 November 2020|archive-url=https://web.archive.org/web/20201128201553/https://www.ox.ac.uk/news/2020-02-07-oxford-team-begin-novel-coronavirus-vaccine-research|url-status=live}}</ref><ref name="ox.ac.uk_2020-02-07">{{cite web|date=7 February 2020|title=Oxford team to begin novel coronavirus vaccine research|url=https://www.ox.ac.uk/news/2020-02-07-oxford-team-begin-novel-coronavirus-vaccine-research|access-date=28 November 2020|publisher=University of Oxford|archive-date=28 November 2020|archive-url=https://web.archive.org/web/20201128201553/https://www.ox.ac.uk/news/2020-02-07-oxford-team-begin-novel-coronavirus-vaccine-research|url-status=live}}</ref>

د اکسفورډ پوهنتون او اسټرازېنکا شرکت تر منځ د غیر انتفاعي مجوز یو لومړنی تړون د ۲۰۲۰ کال په مې میاشت کې لاسلیک شو چې په ټولیز ډول یو میلیارد ډوزه وو او په دې کې ۱۰۰ میلیون ډوزه د بریتانیا د لاسرسي لپاره ریزرف وو. پر دې سربېره متحدو ایالتونو ۳۰۰ میلیون ډوزونه او د درېیم پړاو ازمېښتونه په متحدو ایالتونو کې ریزرف کړي وو. د دغه ګډ کار لپاره ۶۸ میلیونه پونډه د بریتانیا د دولت له بودیجې څخه او ۱.۲ میلیارده ډالره د متحدو ایالتونو د حکومت له بودیجې څخه د واکسین د جوړولو لپاره ځانګړل شول. د ۲۰۲۰ کال په جون میاشت کې د متحدو ایالتونو د الرژي او ساري ناروغیو ملي انستېتیوت (NIAID) تایید کړه چې د واکسین د ازمېښتونو درېیم پړاو د ۲۰۲۰ کال په جولای میاشت کې پیلېږي. د جون په ۴مه نېټه اسټرازېنکا شرکت وویل چې کوواکس (COVAX) پروګرام واکسین ته د عادلانه لاسرسي لپاره د روغتیا د نړیوال سازمان له‌خوا مدیریت کېږي او مالي ملاتړيیې «CEPI» او «GAVI» دي چې ۷۵۰ میلیون ډالره یې په بېوزلو هېوادونو کې د ۳۰۰ میلیون ډوزه واکسین د توزېع لپاره لګولي دي.<ref>{{cite news|title=Oxford/AstraZeneca Covid vaccine research 'was 97% publicly funded'|url=https://www.theguardian.com/science/2021/apr/15/oxfordastrazeneca-covid-vaccine-research-was-97-publicly-funded|access-date=14 August 2021|work=The Guardian|date=15 April 2021}}</ref><ref>{{Cite web|title=AstraZeneca takes next steps towards broad and equitable access to Oxford University's COVID-19 vaccine|url=https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-covid-19-vaccine.html|access-date=30 March 2021|website=www.astrazeneca.com|archive-date=16 April 2021|archive-url=https://web.archive.org/web/20210416001246/https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-covid-19-vaccine.html|url-status=live}}</ref><ref>{{Cite web|title=Oxford University's COVID-19 vaccine: next steps towards broad and equitable global access|url=https://www.ox.ac.uk/news/2020-06-05-oxford-university-s-covid-19-vaccine-next-steps-towards-broad-and-equitable-global|access-date=30 March 2021|website=University of Oxford|archive-date=21 March 2021|archive-url=https://web.archive.org/web/20210321231524/https://www.ox.ac.uk/news/2020-06-05-oxford-university-s-covid-19-vaccine-next-steps-towards-broad-and-equitable-global|url-status=live}}</ref><ref>{{cite web|vauthors=Coleman J|date=10 June 2020|title=Final testing stage for potential coronavirus vaccine set to begin in July|url=https://thehill.com/policy/healthcare/501999-final-testing-stage-for-coronavirus-vaccine-could-begin-in-july-report|access-date=11 June 2020|website=The Hill|archive-date=10 January 2021|archive-url=https://web.archive.org/web/20210110124831/https://thehill.com/policy/healthcare/501999-final-testing-stage-for-coronavirus-vaccine-could-begin-in-july-report|url-status=live}}</ref><ref>{{Cite web|vauthors=Keown C|title=U.S. gives AstraZeneca $1.2 billion to fund Oxford University coronavirus vaccine — America would get 300 million doses beginning in October|url=https://www.marketwatch.com/story/us-gives-astrazeneca-12-billion-to-fund-oxford-university-coronavirus-vaccine-securing-300-million-doses-for-country-from-october-2020-05-21|access-date=30 March 2021|website=MarketWatch|archive-date=26 January 2021|archive-url=https://web.archive.org/web/20210126045250/https://www.marketwatch.com/story/us-gives-astrazeneca-12-billion-to-fund-oxford-university-coronavirus-vaccine-securing-300-million-doses-for-country-from-october-2020-05-21|url-status=live}}</ref>

== سرچينې ==
